GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardiff Oncology Inc (NAS:CRDF) » Definitions » Shiller PE Ratio

Cardiff Oncology (Cardiff Oncology) Shiller PE Ratio : (As of Apr. 27, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Cardiff Oncology Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cardiff Oncology Shiller PE Ratio Historical Data

The historical data trend for Cardiff Oncology's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiff Oncology Shiller PE Ratio Chart

Cardiff Oncology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cardiff Oncology Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cardiff Oncology's Shiller PE Ratio

For the Biotechnology subindustry, Cardiff Oncology's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardiff Oncology's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cardiff Oncology's Shiller PE Ratio falls into.



Cardiff Oncology Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Cardiff Oncology's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Cardiff Oncology's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.21/129.4194*129.4194
=-0.210

Current CPI (Dec. 2023) = 129.4194.

Cardiff Oncology Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -12.240 99.695 -15.889
201406 -12.240 100.560 -15.753
201409 -20.160 100.428 -25.980
201412 -18.000 99.070 -23.514
201503 -23.760 99.621 -30.867
201506 -29.520 100.684 -37.945
201509 -16.560 100.392 -21.348
201512 -18.720 99.792 -24.278
201603 -25.920 100.470 -33.388
201606 -24.480 101.688 -31.156
201609 -24.480 101.861 -31.103
201612 -24.480 101.863 -31.103
201703 -23.040 102.862 -28.989
201706 -18.720 103.349 -23.442
201709 -8.460 104.136 -10.514
201712 -4.320 104.011 -5.375
201803 -6.230 105.290 -7.658
201806 -5.270 106.317 -6.415
201809 -1.100 106.507 -1.337
201812 -1.090 105.998 -1.331
201903 -1.020 107.251 -1.231
201906 -0.760 108.070 -0.910
201909 -0.690 108.329 -0.824
201912 -0.510 108.420 -0.609
202003 -0.410 108.902 -0.487
202006 -0.510 108.767 -0.607
202009 -0.190 109.815 -0.224
202012 -0.180 109.897 -0.212
202103 -0.140 111.754 -0.162
202106 -0.170 114.631 -0.192
202109 -0.170 115.734 -0.190
202112 -0.230 117.630 -0.253
202203 -0.250 121.301 -0.267
202206 -0.240 125.017 -0.248
202209 -0.200 125.227 -0.207
202212 -0.200 125.222 -0.207
202303 -0.250 127.348 -0.254
202306 -0.250 128.729 -0.251
202309 -0.220 129.860 -0.219
202312 -0.210 129.419 -0.210

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cardiff Oncology  (NAS:CRDF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Cardiff Oncology Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Cardiff Oncology's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardiff Oncology (Cardiff Oncology) Business Description

Traded in Other Exchanges
Address
11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.
Executives
Gary W Pace director C/O RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Fairooz Kabbinavar officer: Chief Medical Officer C/O TOCAGEN INC., 4242 CAMPUS POINT COURT, STE. 500, SAN DIEGO CA 92121
Mark Erlander officer: Chief Scientific Officer C/O TROVAGENE, INC., 11055 FLINTKOTE AVENUE, SUITE A, SAN DIEGO CA 92121
Lale White director 310 GODDARD, SUITE 150, IRVINE CA 92618
James O Armitage director C/O TESARO, INC., 1000 WINTER ST., SUITE 3300, WALTHAM MA 02451
James E. Levine officer: Chief Financial Officer 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Renee P Tannenbaum director 9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Tod Smeal officer: Chief Scientific Officer 11055 FLINTKOTE AVENUE, SA DIEGO CA 92121
Katherine L Ruffner officer: Chief Medical Officer 11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121
Mani Mohindru director C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Rodney S Markin director C/O UNIVERSITY OF NEBR MEDICAL CENTER, 983135 NEBRASKA MEDICAL CENTER, OMAHA NE 68198-3135
Gary S Jacob director
Vicki Kelemen officer: Exec. VP and COO 11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121
John P Brancaccio director C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116